Table 6 Risk of colorectal cancer, overall and according to clinicopathological factors, in relation to oral contraceptive (OC) use
Tumour subgroups | OC use | n | HR crude | p | HR adjusted | p |
|---|---|---|---|---|---|---|
CRC | No | 194 | 1.00 | 1.00 | ||
OC | 107 | 0.56(0.44-0.71) | <0.001 | 1.05(0.80-1.37) | 0.738 | |
T stage 1 & 2 | No | 45 | 1.00 | 1.00 | ||
OC | 17 | 0.39(0.22-0.68) | 0.001 | 0.69(0.37-1.28) | 0.239 | |
T stage 3 & 4 | No | 127 | 1.00 | 1.00 | ||
OC | 77 | 0.62(0.47-0.82) | 0.001 | 1.21(0.87-1.67) | 0.254 | |
N0 | No | 105 | 1.00 | 1.00 | ||
OC | 46 | 0.45(0.32-0.63) | <0.001 | 0.82(0.56-1.22) | 0.328 | |
N1 & N2 | No | 60 | 1.00 | 1.00 | ||
OC | 45 | 0.78(0.52-1.13) | 0.176 | 1.36(0.88-2.11) | 0.173 | |
M0 | No | 150 | 1.00 | 1.00 | ||
OC | 85 | 0.58(0.44-0.75) | <0.001 | 1.05(0.78-1.42) | 0.744 | |
M1 | No | 38 | 1.00 | 1.00 | ||
OC | 17 | 0.46(0.26-0.81) | 0.007 | 0.90(0.47-1.70) | 0.734 | |
beta-catenin+ | No | 105 | 1.00 | 1.00 | ||
OC | 51 | 0.50(0.35-0.70) | <0.001 | 0.97(0.66-1.41) | 0.853 | |
beta-catenin− | No | 61 | 1.00 | 1.00 | ||
OC | 42 | 0.70(0.47-1.04) | 0.076 | 1.31(0.84-2.05) | 0.232 | |
cyclin D1+ | No | 138 | 1.00 | 1.00 | ||
OC | 75 | 0.55(0.42-0.74) | <0.001 | 1.16(0.85-1.60) | 0.351 | |
cyclin D1− | No | 30 | 1.00 | 1.00 | ||
OC | 15 | 0.51(0.27-0.94) | 0.032 | 0.63(0.32-1.27) | 0.199 | |
p53+ | No | 81 | 1.00 | 1.00 | ||
OC | 46 | 0.58(0.41-0.83) | 0.003 | 1.06(0.70-1.60) | 0.744 | |
p53− | No | 88 | 1.00 | 1.00 | ||
OC | 45 | 0.52(0.36-0.74) | <0.001 | 1.04(0.70-1.56) | 0.840 | |
MSI | No | 28 | 1.00 | 1.00 | ||
OC | 17 | 0.62(0.34-1.13) | 0.117 | 1.78(0.92-3.47) | 0.088 | |
MSS | No | 136 | 1.00 | 1.00 | ||
OC | 74 | 0.56(0.42-0.74) | <0.001 | 0.98(0.71-1.36) | 0.912 |